Full Text View
Tabular View
No Study Results Posted
Related Studies
Myocardial Infarction and Current Oral Contraceptive Use
This study has been completed.
First Received: May 25, 2000   Last Updated: June 23, 2005   History of Changes
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00005241
  Purpose

To assess whether current oral contraceptive (OC) use (within the previous month) increased the risk of myocardial infarction. Also, to assess the combined effects of cigarette smoking and oral contraceptive use.


Condition
Cardiovascular Diseases
Coronary Disease
Myocardial Infarction
Heart Diseases

MedlinePlus related topics: Coronary Artery Disease Heart Attack Heart Diseases
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: April 1989
Estimated Study Completion Date: December 1999
Detailed Description:

BACKGROUND:

It has been established that oral contraceptive formulations used in the 1960s and 1970s increased the risks of myocardial infarction, venous thromboembolism, and stroke. Oral contraceptive formulations have changed, as have prescribing practices, and there was a need for information on the effects of the newer formulations in use. Myocardial infarction is the most important cardiovascular disease in terms of the incidence and mortality attributed to use of oral contraceptives; although the overall incidence of myocardial infarction is relatively low in women of childbearing ages, the incidence is not low in smokers.

DESIGN NARRATIVE:

A case-control design was used. The case series consisted of women 18 to 44 years of age admitted for a documented first myocardial infarction to any of 100 collaborating hospitals in Massachusetts, Rhode Island, and Pennsylvania. Nurse interviewers administered standard structured questionnaires to cases and controls on drug use, race, religion, medical history and myocardial infarction risk factors. Information was collected on: cigarette smoking; histories of hypertension, diabetes mellitus, angina, abnormal plasma lipids; reproductive and menstrual histories; alcohol and coffee consumption; personality type using the Framingham Type A scale; family history of myocardial infarction; exercise; education and occupation of the patient and her spouse. Information was also obtained on the timing and duration of oral contraceptive use. The effect of oral contraceptive use was considered among nonsmokers, light smokers, and heavy smokers. Individual oral contraceptive formulations were classified according to dosage and type of estrogen, formulation type, and other groupings. Multiple logistic regression analysis with fitting of the regression equations by the method of maximum likelihood was used for simultaneous control of all potential confounding factors.

The study was renewed in 1995 to continue data collection to establish the effect of triphasic OCs on MI risk, with particular attention to the joint effect with heavy smoking. The new data collection also permitted more definitive analysis of the effect of monophasic OCs. Triphasic formulations have become popular and in 1995 accounted for about half of OC use. There were not enough users of triphasic OCs in the present study for informative analysis, nor were there any data from other studies on this issue. The study ended in December, 1999.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
No Contacts or Locations Provided
  More Information

Publications:
Study ID Numbers: 1122
Study First Received: May 25, 2000
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00005241     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Arterial Occlusive Diseases
Heart Diseases
Contraceptive Agents
Myocardial Ischemia
Contraceptives, Oral
Contraceptive Agents, Female
Vascular Diseases
Ischemia
Arteriosclerosis
Coronary Disease
Necrosis
Infarction
Myocardial Infarction
Coronary Artery Disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Heart Diseases
Contraceptive Agents
Myocardial Ischemia
Physiological Effects of Drugs
Contraceptives, Oral
Contraceptive Agents, Female
Vascular Diseases
Reproductive Control Agents
Arteriosclerosis
Ischemia
Pharmacologic Actions
Coronary Disease
Necrosis
Pathologic Processes
Therapeutic Uses
Cardiovascular Diseases
Infarction
Myocardial Infarction
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 07, 2009